Rusfertide Reduces Need for Phlebotomy in Polycythemia Vera

Rusfertide Reduces Need for Phlebotomy in Polycythemia Vera

(MedPage Today) -- CHICAGO -- The use of the investigational weekly subcutaneous injection rusfertide significantly reduced the need for phlebotomy among polycythemia vera patients who had been dependent on it, the VERIFY phase III trial showed...

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 1, 2025-

In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL

Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.

Rusfertide Combo Enhances Responses in Polycythemia Vera

Phase 3 VERIFY study findings showed rusfertide maintained a manageable safety profile consistent with previous studies.

Integrating Novel Agents: Clinical Positioning of Hepcidin Mimetics

Panelists discuss how hepcidin mimetics like rusfertide complement existing therapies in polycythemia vera (PV) by regulating iron metabolism, reducing iron overload, and balancing erythropoiesis, which can enhance the effectiveness of cytoreductive treatments, alleviate symptoms like fatigue and splenomegaly, and improve quality of life, particularly in patients with refractory disease or those requiring frequent phlebotomy.

Breakthrough PV Drug Rusfertide Doubles Response Rates in Phase 3 Trial, ASCO Data Reveals

New Phase 3 data shows rusfertide reduces phlebotomy needs by 3x and improves hematocrit control in PV patients. See full ASCO presentation details.